Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172475 | 0.96 | ALDH1A1 (0.51) | ALDH1A1MAPTCHRM4POLBRAD52 | |
| SCHEMBL5128957 | 0.94 | CHRM4 (0.48) | ALDH1A1MAPTCHRM4SMN1; SMN2GAA | |
| SCHEMBL5118790 | 0.92 | CHRM4 (0.47) | ALDH1A1MAPTCHRM4POLBRAD52 | |
| SCHEMBL7173140 | 0.90 | CHRM4 (0.45) | ALDH1A1MAPTCHRM4SMN1; SMN2GAA | |
| SCHEMBL7176321 | 0.88 | CHRM4 (0.44) | ALDH1A1MAPTCHRM4POLBRAD52 | |
| SCHEMBL5119073 | 0.85 | CHRM4 (0.48) | ALDH1A1MAPTCHRM4SMN1; SMN2ESR1 | |
| SCHEMBL5128673 | 0.84 | GAA (0.50) | ALDH1A1SMN1; SMN2GAARXFP1ESR1 | |
| SCHEMBL5129562 | 0.83 | SMN1; SMN2 (0.47) | ALDH1A1MAPTCHRM4POLBRAD52 | |
| SCHEMBL5122516 | 0.83 | ESR1 (0.64) | ALDH1A1MAPTCHRM4ESR1PDE5A | |
| SCHEMBL5123014 | 0.83 | PRKCI (0.58) | ALDH1A1MAPTCHRM4POLBRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| EP-0934321-B1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| CN-1081638-C | Thienopyrimidine compounds | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | CN | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| US-5948911-A | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| CN-1227560-A | Thienopyrimidines | MERCK PATENT GMBH (DE) | 1999-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | ALDH1A1 1055/4885MAPT 2997/4885CHRM4 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.